ALEXANDRIA
Isogenica Ltd
Application Filed: 2017-10-16
Trademark Application Details
PUBLISHED FOR OPPOSITION
| Research |
OneLook
Acronym Finder
|
| Serial Number | 87646697 |
| Registration Number | 5700446 |
| Mark Drawing Code | 4000: Illustration: Drawing with word(s)/letter(s)/number(s) in Block form |
| Domestic Representative | Joel D. Leviton |
| Attorney Name | Joel D. Leviton |
| Law Office Assigned | N10 |
| Employee Name | CROWLEY, PAUL C |
Timeline
| 2017-10-16 | Application Filed |
| 2018-11-26 | Location: PUBLICATION AND ISSUE SECTION |
| 2019-01-01 | Published for Opposition |
| 2019-01-01 | Status: Live/Pending |
| 2019-01-01 | Transaction Date |
| 2019-03-19 | Trademark Registered |
Trademark Applicants & Owners
| Owner: |  Isogenica Ltd |
| Entity Statement | private limited company |
| Address | Chesterford Research Park, The Mansion Little Chesterford Saffron Walden, Es GB CB10-1XL |
| Legal Entity Type | |
| Legal Entity State | GB |
Documents
Click the blue "Refresh" button to load certificates, specimines, application, and other documents.
Attorney of Record
Good, Services, and Codes
| International Codes: | 1 |
| U.S. Codes: | 001,005,006,010,026,046 |
| International Codes: | 5 |
| U.S. Codes: | 006,018,044,046,051,052 |
| Type Code | Type |
|---|---|
| GS0051 | Diagnostic and therapeutic peptides, proteins, molecules, antibodies, polypeptides and polymers for the treatment of infectious, inflammatory and autoimmune disorders, cancer, metabolic and endocrine, cardiovascular disorders and hemostatic disorders; biochemical and biological substances for medical diagnostics and analysis, namely, diagnostic agents and reagents; pharmaceutical preparations and substances for the treatment of infectious, inflammatory and autoimmune disorders, cancer, metabolic and endocrine, cardiovascular disorders and hemostatic disorders; chemical preparations in the nature of reagents for use in DNA medical diagnostic analysis; nucleic acid sequences for medical use; synthetic peptides for pharmaceutical purposes for the treatment of infectious, inflammatory and autoimmune disorders, cancer, metabolic and endocrine, cardiovascular disorders and hemostatic disorders |
| GS0011 | Antibody reagents for scientific purposes; nucleic acids for scientific purposes; clinical diagnostic reagents and clinical diagnostic reagent kits comprised primarily of monoclonal antibodies and monoclonal antibody fragments, buffers and reagents to detect the presence of antibody target antigens in human or animal tissues, or to detect the presence of therapeutic proteins or replacement enzymes in human or animal tissues for scientific laboratory use; chemical preparations for use in DNA analysis other than for medical or veterinary purposes; proteins for use in discovery, optimization and preclinical development of therapeutic and diagnostic antibodies using recombinant DNA technology other than for medical use; enzymes for use in the continuous homogenous isothermal amplifications of specific DNA templates other than for medical use; proteins for detecting antibodies other than for medical use; reagents for medical research; diagnostic preparations for scientific or research use; chemical reagents for use in genetic research |
Trademark Filing History
| Description | Date | Event Coding |
|---|---|---|
| NEW APPLICATION ENTERED IN TRAM | 2017-10-19 | 1 NWAP I:Incoming Correspondence |
| NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 2017-10-25 | 2 NWOS I:Incoming Correspondence |
| ASSIGNED TO EXAMINER | 2018-01-25 | 3 DOCK D:Assigned to Examiner |
| NON-FINAL ACTION WRITTEN | 2018-01-31 | 4 CNRT R:Renewal |
| NON-FINAL ACTION E-MAILED | 2018-01-31 | 5 GNRT F:First Action |
| NOTIFICATION OF NON-FINAL ACTION E-MAILED | 2018-01-31 | 6 GNRN O:Outgoing Correspondence |
| TEAS RESPONSE TO OFFICE ACTION RECEIVED | 2018-05-14 | 7 TROA I:Incoming Correspondence |
| ASSIGNED TO LIE | 2018-05-21 | 8 ALIE A:Allowance for Publication |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2018-05-23 | 9 CRFA I:Incoming Correspondence |
| TEAS/EMAIL CORRESPONDENCE ENTERED | 2018-05-23 | 10 TEME I:Incoming Correspondence |
| FINAL REFUSAL WRITTEN | 2018-06-04 | 11 CNFR R:Renewal |
| FINAL REFUSAL E-MAILED | 2018-06-04 | 12 GNFR O:Outgoing Correspondence |
| NOTIFICATION OF FINAL REFUSAL EMAILED | 2018-06-04 | 13 GNFN O:Outgoing Correspondence |
| TEAS REQUEST FOR RECONSIDERATION RECEIVED | 2018-11-08 | 14 ERFR I:Incoming Correspondence |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2018-11-08 | 15 CRFA I:Incoming Correspondence |
| TEAS/EMAIL CORRESPONDENCE ENTERED | 2018-11-09 | 16 TEME I:Incoming Correspondence |
| APPROVED FOR PUB - PRINCIPAL REGISTER | 2018-11-20 | 17 CNSA O:Outgoing Correspondence |
| NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | 2018-12-12 | 18 NONP E:E-Mail |
| PUBLISHED FOR OPPOSITION | 2019-01-01 | 19 PUBO A:Allowance for Publication |
| OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | 2019-01-01 | 20 NPUB E:E-Mail |
| REGISTERED-PRINCIPAL REGISTER | 2019-03-19 | 21 R.PR A:Allowance for Publication |
| COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | 2024-03-19 | 22 REM1 E:E-Mail |
Similar Marks
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 